Document:

Exhibit 4.5

WC-1                                                    Warrant to Purchase
                                                          **           **
                                                       Shares of Common Stock

THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THIS
WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.
THIS WARRANT AND THE COMMON STOCK ISSUABLE UPON SUCH EXERCISE MAY NOT BE SOLD,
OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE
REGISTRATION STATEMENT AS TO THIS WARRANT UNDER SAID ACT AND ANY APPLICABLE
STATE SECURITIES LAW OR AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF SUCH
ACT AND SUCH STATE SECURITIES LAWS, AND THE INVESTOR SHALL HAVE DELIVERED TO THE
ISSUING COMPANY AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE ISSUING
COUNSEL AS TO THE AVAILABILITY OF SUCH EXEMPTION.

           Void after 5:30 P.M. New York City time on January 24, 2011

                     SERIES C COMMON STOCK PURCHASE WARRANT

                                       OF

                         LAWRENCE CONSULTING GROUP, INC.

      This is to certify that, FOR VALUE RECEIVED,                         , or
registered assigns ("Holder"), is entitled to purchase, on the terms and subject
to the provisions of this Warrant, from Lawrence Consulting Group, Inc., a
Delaware corporation (the "Company"), at an exercise price (the "Exercise
Price") of seventy three and 44/100 cents ($.7344) per share,
(        ) shares of common stock, par value $.0001 per share ("Common Stock"),
of the Company at any time during the period (the "Exercise Period") commencing
on the date of this Warrant and ending at 5:30 P.M. New York City time, on
January 24, 2009; provided, however, that if such date is a day on which banking
institutions in the State of New York are authorized by law to close, then on
the next succeeding day which such banks are not authorized to close. The number
of shares of Common Stock to be issued upon the exercise or conversion of this
Warrant and the price to be paid for a share of Common Stock may be adjusted
from time to time in the manner set forth in this Warrant. The shares of Common
Stock deliverable upon such exercise or conversion, and as adjusted from time to
time, are hereinafter sometimes referred to as "Warrant Shares," and the
exercise price for the purchase of a share of Common Stock pursuant to this
Warrant in effect at any time, as the same may be adjusted from time to time, is
hereinafter sometimes referred to as the "Exercise Price." This Warrant was
issued pursuant to a subscription agreement (the "Subscription Agreement")
between the Company and the initial holder of this Warrant.

      1. Exercise of Warrant. This Warrant may be exercised in whole at any time
or in part from time to time during the Exercise Period by presentation and
surrender hereof to the Company at its principal office, or at the office of its
stock transfer agent, if any, with the Purchase Form annexed hereto duly
executed and accompanied by payment of the Exercise Price for the number of
shares of Common Stock specified in such form. Payment of the Exercise Price may
be made either by check (subject to collection) or wire transfer in the amount
of the Exercise Price. If this Warrant should be exercised in part only, the
Company shall, upon surrender of this Warrant for cancellation, execute and
deliver a new

<PAGE>

Warrant evidencing the rights of the Holder hereof to purchase the balance of
the shares of Common Stock purchasable hereunder. Upon receipt by the Company of
this Warrant at its office, or by the stock transfer agent of the Company at its
office, in proper form for exercise, or upon delivery of the notice of
conversion or exercise without delivery of this Warrant as provided in the
Purchase Agreement, the Holder shall be deemed to be the holder of record of the
shares of Common Stock issuable upon such exercise, notwithstanding that the
stock transfer books of the Company shall then be closed or that certificates
representing such shares of Common Stock shall not then be actually delivered to
the Holder.

      2. Reservation of Shares. The Company hereby agrees that at all times
there shall be reserved for issuance upon exercise of this Warrant such number
of shares of Common Stock as shall be required for issuance and delivery upon
exercise or conversion of this Warrant and that it shall not increase the par
value of the Common Stock.

      3. Fractional Shares. No fractional shares or script representing
fractional shares shall be issued upon the exercise of this Warrant. With
respect to any fraction of a share called for upon any exercise or conversion of
this Warrant, the Company shall round the number of shares of Common Stock to be
issued to the next higher integral number of shares

      4. Exchange, Transfer, Assignment or Loss of Warrant. This Warrant is
exchangeable, without expense, at the option of the Holder, upon presentation
and surrender hereof to the Company or at the office of its stock transfer
agent, if any, for other Warrants of different denominations entitling the
holder thereof to purchase in the aggregate the same number of shares of Common
Stock purchasable hereunder. Subject to the provisions of Section 11 of this
Warrant, upon surrender of this Warrant to the Company or at the office of its
stock transfer agent, if any, with the Assignment Form annexed hereto duly
executed and funds sufficient to pay any transfer tax, the Company shall,
without charge, execute and deliver a new Warrant in the name of the assignee
named in such instrument of assignment and this Warrant shall promptly be
canceled. This Warrant may be divided or combined with other Warrants which
carry the same rights upon presentation hereof at the office of the Company or
at the office of its stock transfer agent, if any, together with a written
notice specifying the names and denominations in which new Warrants are to be
issued and signed by the Holder hereof. The term "Warrant" as used herein
includes any Warrants into which this Warrant may be divided or exchanged. Upon
receipt by the Company of evidence satisfactory to it of the loss, theft,
destruction or mutilation of this Warrant, and (in the case of loss, theft or
destruction) of reasonably satisfactory indemnification, and upon surrender and
cancellation of this Warrant, if mutilated, the Company will execute and deliver
a new Warrant of like tenor. Any such new Warrant executed and delivered shall
constitute an additional contractual obligation on the part of the Company,
whether or not this Warrant so lost, stolen, destroyed, or mutilated shall be at
any time enforceable by anyone.

      5. Rights of the Holder. The Holder shall not, by virtue of this Warrant,
be entitled to any rights of a stockholder in the Company, either at law or
equity, and the rights of the Holder are limited to those expressed in the
Warrant, the Purchase Agreement and the Registration Rights Agreement and are
not enforceable against the Company except to the extent set forth herein and
therein.

      6. Adjustments To Exercise Price. The Exercise Price in effect at any time
and the number and kind of securities purchasable upon exercise of each Warrant
shall be subject to adjustment as follows:

                                      -2-
<PAGE>

      (a) In case the Company shall, subsequent to the effectiveness of a
two-for-one stock distribution on or about the date of the closing pursuant to
the Subscription Agreement whereby the Company issued one additional share of
Common Stock for each share of Common Stock outstanding on the record date, (i)
pay a dividend or make a distribution on its shares of Common Stock in shares of
Common Stock, (ii) subdivide or reclassify its outstanding Common Stock into a
greater number of shares or otherwise effect a stock split or distribution, or
(iii) combine or reclassify its outstanding Common Stock into a smaller number
of shares or otherwise effect a reverse split, the Exercise Price in effect at
the time of the record date for such dividend or distribution or of the
effective date of such subdivision, combination or reclassification shall be
proportionately adjusted so that the Holder of this Warrant exercised after such
date shall be entitled to receive the aggregate number and kind of shares which,
if this Warrant had been exercised immediately prior to such time, he would have
owned upon such exercise and been entitled to receive upon such dividend,
subdivision, combination or reclassification. Such adjustment shall be made
successively whenever any event listed in this Section 6(a) shall occur.

      (b) Whenever the Exercise Price payable upon exercise of each Warrant is
adjusted pursuant to this Section 6, the number of shares of Common Stock
issuable upon exercise or conversion of this Warrant shall simultaneously be
adjusted by multiplying the number of shares of Common Stock issuable upon
exercise of each Warrant in effect on immediately prior to the adjustment by the
Exercise Price then in effect and dividing the product so obtained by the
Exercise Price, as adjusted. In no event shall the Exercise Price per share be
less than the par value per share, and, if any adjustment made pursuant to said
Section 6 would result in an Exercise Price which would be less than the par
value per share, then, in such event, the Exercise Price per share shall be the
par value per share; provided, however, that the limitation contained in this
sentence shall not affect the number of shares of Common Stock issuable upon
exercise or conversion of this Warrant.

      (c) In the event that at any time, as a result of an adjustment made
pursuant to this Section 6, the Holder of any Warrant thereafter shall become
entitled to receive any shares of the Company, other than Common Stock,
thereafter the number of such other shares so receivable upon exercise of any
Warrant shall be subject to adjustment from time to time in a manner and on
terms as nearly equivalent as practicable to the provisions with respect to the
Common Stock contained in this Sections 6.

      (d) Irrespective of any adjustments in the Exercise Price or the number or
kind of shares purchasable upon exercise of Warrants, Warrants theretofore or
thereafter issued may continue to express the same price and number and kind of
shares as are stated in this and similar Warrants initially issued by the
Company.

      7. Officer's Certificate. Whenever the Exercise Price shall be adjusted as
required by the provisions of Section 6 of this Warrant, the Company shall
forthwith file in the custody of its Secretary or an Assistant Secretary at its
principal office and with its stock transfer agent, if any, an officer's
certificate showing the adjusted Exercise Price and the adjusted number of
shares of Common Stock issuable upon exercise of each Warrant, determined as
herein provided, setting forth in reasonable detail the facts requiring such
adjustment, including a statement of the number of additional shares of Common
Stock, if any, and such other facts as shall be necessary to show the reason for
and the manner of computing such adjustment. Each such officer's certificate
shall be made available at all reasonable times for inspection by the Holder,
and the Company shall, forthwith after each such adjustment, mail, by certified
mail, return receipt requested and by telecopier and e-mail, a copy of such
certificate to the Holder at the Holder's address set forth in the Company's
Warrant Register.

                                      -3-
<PAGE>

      8. Notices To Warrant Holders. So long as this Warrant shall be
outstanding, (a) if the Company shall pay any dividend or make any distribution
upon Common Stock (other than a regular cash dividend payable out of retained
earnings) or (b) if the Company shall offer to the holders of Common Stock for
subscription or purchase by them any share of any class or any other rights or
(c) if any capital reorganization of the Company, reclassification of the
capital stock of the Company, consolidation or merger of the Company with or
into another corporation, sale, lease or transfer of all or substantially all of
the property and assets of the Company to another corporation, or voluntary or
involuntary dissolution, liquidation or winding up of the Company shall be
effected, then in any such case, the Company shall cause to be mailed by
certified mail, return receipt requested, to the Holder, at least fifteen days
prior to the date specified in clauses (i) and (ii), as the case may be, of this
Section 8 a notice containing a brief description of the proposed action and
stating the date on which (i) a record is to be taken for the purpose of such
dividend, distribution or rights, or (ii) such reclassification, reorganization,
consolidation, merger, conveyance, lease, dissolution, liquidation or winding up
is to take place and the date, if any is to be fixed, as of which the holders of
Common Stock or other securities shall receive cash or other property
deliverable upon such reclassification, reorganization, consolidation, merger,
conveyance, dissolution, liquidation or winding up.

      9. Reclassification, Reorganization or Merger. In case of any
reclassification, capital reorganization or other change of outstanding shares
of Common Stock of the Company, or in case of any consolidation or merger of the
Company with or into another corporation (other than a merger in which the
Company is the continuing corporation and which does not result in any
reclassification, capital reorganization or other change of outstanding shares
of Common Stock of the class issuable upon exercise of this Warrant) or in case
of any sale, lease or conveyance to another corporation of the property of the
Company as an entirety, the Company shall, as a condition precedent to such
transaction, cause effective provisions to be made so that the Holder shall have
the right thereafter by exercising this Warrant, to purchase the kind and amount
of shares of stock and other securities and property receivable upon such
reclassification, capital reorganization and other change, consolidation,
merger, sale or conveyance by a holder of the number of shares of Common Stock
which might have been purchased upon exercise of this Warrant immediately prior
to such reclassification, change, consolidation, merger, sale or conveyance. Any
such provision shall include provision for adjustments which shall be as nearly
equivalent as may be practicable to the adjustments provided for in this
Warrant. The foregoing provisions of this Section 9 shall similarly apply to
successive reclassifications, capital reorganizations and changes of shares of
Common Stock and to successive consolidations, mergers, sales or conveyances.
Notwithstanding the foregoing, in the event that, as a result of any merger,
consolidation, sale of assets or similar transaction, all of the holders of
Common Stock receive and are entitled to receive no consideration other than
cash in respect of their shares of Common Stock, then, at the effective time of
the transaction, the rights to purchase Common Stock pursuant to the Warrants
shall terminate, and the holders of the Warrants shall, notwithstanding any
other provisions of this Warrant, receive in respect of each Warrant to purchase
one (1) share of Common Stock, upon presentation of the Warrant Certificate, the
amount by which the consideration per share of Common Stock payable to the
holders of Common Stock at such effective time exceeds the Exercise Price in
effect on such effective date, without giving effect to the transaction. In the
event that, in such a transaction, the value of the consideration to be received
per share of Common Stock is equal to or less than the Exercise Price, the
Warrants shall automatically terminate and no consideration will be paid with
respect thereof.

      10. Piggy-Back Registration Rights.

                                      -4-
<PAGE>

      (a) In the event that, at any time during the period six months after the
effective date of the Investor Registration Statement and ending December 31,
2008, the Company registers its securities pursuant to the Securities Act of
1933, as amended (the "Securities Act"), in connection with a public offering of
its securities (other than a registration statement on Form S-4 or S-8 or
subsequent similar forms), the Company shall advise the registered holders of
the Warrants or the Warrant Shares (each such person being referred to herein as
a "holder") by written notice at least two (2) weeks prior to the filing of any
registration statement under the Securities Act covering any securities of the
Company and will upon the request of any such holder include in any such
registration statement such information as may be required to permit a public
offering of the Warrant Shares; provided, however, that the Company shall not be
required to include such Warrant Shares in a registration statement relating
solely to an offering by the Company of securities for its own account if the
managing underwriter shall have advised the Company in writing that the
inclusion of such Warrant Shares will have a material adverse effect upon the
ability of the Company to sell securities for its own account, and provided,
further, that the holders are not treated less favorably than others having
piggyback registration rights. The Company shall keep the registration statement
current and effective for the holders for such period as it is keeping it
effective for other selling stockholders or such earlier date as all of the
registered Warrant Shares shall have been sold. In connection with such
registration, if requested by the managing underwriter as a condition to the
inclusion of the Warrant Shares in the registration statement, the holders shall
agree not to sell or otherwise distribute the Warrant Shares pursuant to the
registration statement for such period not to exceed ninety (90) days (the
"lock-up period") as the managing underwriter shall request, in which event the
Company will keep the registration statement current and effective for nine (9)
months after the expiration of the lock-up period or such earlier date as all of
the registered Warrant Shares shall have been sold. If the Company is eligible
to register the Warrant Shares on a Form S-3 or similar short-form registration
statement, the Company shall use such form and shall keep the registration
statement current and effective until all of the Warrant Shares shall have been
sold. The term "Investor Registration Statement" shall mean the registration
statement filed by the Company with respect to the shares of Common Stock
issuable upon conversion of the Company's Series A Convertible Preferred Stock
and upon exercise of the warrants that were issued in the Company's January 2006
private placement.

      (b) It shall be a condition to the inclusion of a holder's Warrant Warrant
Shares in a registration statement pursuant to this Section 10 that the holder
shall:

      (i) furnish the information and indemnification as set forth in these
Registration Rights Provisions and update such information immediately upon the
occurrence of any events or condition which make the information concerning the
Holder inaccurate in any material respect;

      (ii) not sell any Warrant Shares pursuant to the registration statement
except in the manner set forth in the registration statement;

      (iii) comply with all applicable prospectus delivery requirements and
provisions of Regulation M of the Commission pursuant to the Securities Act;

      (iv) not sell or otherwise transfer or distribute any Warrant Shares if
the holder possesses any material nonpublic information concerning the Company;

      (v) not sell or otherwise transfer any Warrant Shares pursuant to a
registration statement upon receipt of advice from the Company that the
registration statement is no longer current until the holder is advised that the
Warrant Shares may be sold pursuant to the registration statement; and

                                      -5-
<PAGE>

      (vi) provide any other information requested by the Commission, the NASD,
any stock exchange or market on which the Common Stock is traded and any state
securities commission.

      (c) Notwithstanding the provisions of Section 10(a) of this Warrant, the
Company's obligations to keep a registration statement current and effective
shall be suspended for an Excusable Reason, as hereinafter defined. If an
Excusable Reason shall occur, the Company shall give the holders prompt notice
thereof, and, the holders shall refrain from thereafter making sales pursuant to
the registration statement until the cessation of the Excusable Reason. An
"Excusable Reason" shall mean the " means the occurrence of negotiations with
respect to a material agreement prior to either the announcement of the
execution of the agreement or the termination of the negotiations with respect
to such proposed agreement and other similar material corporate events to which
the Company is a party or expects to be a party if, in the reasonable judgment
of the Company, disclosure of the negotiations or other event would be adverse
to the best interests of the Company provided that the Company is continuing to
treat such negotiations as confidential and provided further that the period
during which the Company is precluded from filing the registration statement (or
suspended the use of an effective registration statement) as a result thereof
has not exceeded ninety (90) days and provided further that the Company shall
not be permitted to avoid filing a registration statement (or to suspend the use
of an effective registration statement) for an Excusable Reason more than twice
in any one-year period. In the event that the use of a registration statement is
suspended for an Excusable Reason, the period during which the registration
statement shall be kept current and effective shall be extended for the number
of days that the use of the registration statement is suspended for an Excusable
Reason; provided, that the Company shall not be required to keep the
registration statement current and effective subsequent to the January 31, 2009.
The Company shall advise the holders in writing of the occurrence and
termination of an Excusable Reason. The Company shall not be in violation of
this Section 10 if such delays exceed those provided for in this Section 10(c)
and are caused by action or inaction by the Commission, the National Association
of Securities Dealers, Inc., NASD Regulation, Inc., any stock exchange or market
or any state securities commission or any holder.

      (d) The Company shall bear the entire cost and expense of any registration
of securities pursuant to Section 10(a) of this Warrant. Any holder whose
Warrant Shares are included in any such registration statement pursuant to this
Section 10 shall, however, bear any transfer taxes or underwriting discounts or
commissions applicable to the Warrant Shares sold by him pursuant thereto as
well as any fees and disbursements of counsel for the holder.

      (e) (i) n connection with any registration statement filed by the Company
pursuant to this Section 10, Company shall, and hereby agrees to, indemnify and
hold harmless, each Holder and seller of any Warrant Shares covered by such
registration statement and each other person, if any, who controls such Holder
or seller, and their respective directors, officers, partners, agents and
affiliates from and against any and all losses, claims, damages or liabilities,
joint or several, to which they or any of them may become subject under the
Securities Act, the Securities Exchange Act of 1934, as amended (the "Exchange
Act"), or other federal or state statutory law or regulation, at common law or
otherwise, insofar as such losses, claims, damages or liabilities (or actions in
respect thereof), which are collectively referred to as "Losses," arise out of
or are based upon (i) any untrue statement or alleged untrue statement of a
material fact made by the Company contained in the Registration Statement, or
any amendment thereof, or in any Preliminary Prospectus or the Prospectus, or
any amendment thereof or supplement thereto, or in any blue sky application or
other document executed by the Company specifically for that purpose (or based
upon written information furnished by the Company) filed in any state or other
jurisdiction in order to qualify any of the Securities or other Securities under
the securities

                                      -6-
<PAGE>

laws thereof (any such application, document or information being referred to as
a "Blue Sky Application"); or (ii) the omission or alleged omission to state in
any such Registration Statement, Preliminary Prospectus or Prospectus, or
amendment thereof or supplement thereto, or Blue Sky Application a material fact
required to be stated therein or necessary to make the statements made therein
not misleading, and agrees to reimburse each such indemnified party for any
legal or other expenses reasonably incurred by it in connection with
investigating or defending against any such loss, claim, damage, liability or
action; provided, however, that the Company will not be liable in any such case
to the extent that any such loss, claim, damage, or liability arises out of or
is based upon any such untrue statement or alleged untrue statement or omission
or alleged omission made therein or omitted therefrom in reliance upon and in
conformity with written information furnished to the Company by or on behalf of
any holder specifically for use in connection with the preparation thereof, and
further provided, however, that the foregoing indemnity with respect to any
untrue statement, alleged untrue statement, omission, or alleged omission
contained in any Preliminary Prospectus shall not inure to the benefit of any
holder from whom the person asserting any such loss, claims any of, damage, or
liability purchased any of the securities that are the subject thereof (or to
the benefit of any person who controls such holder or other person), if a copy
of the prospectus was not delivered to such person with or prior to the written
confirmation of the sale of such security to such person. The indemnify provided
for in this Section 10(e(i) shall remain in full force and effect regardless of
any investigation made by or on behalf of the indemnified party and shall
survive any transfer of the Warrant Shares by the indemnified party. This
indemnity agreement will be in addition to any liability that the Company may
otherwise have.

      (ii) In connection with any registration statement filed by the Company
pursuant to this Section 10 in which a Holder has registered for sale Warrant
Shares, each holder or seller of Warrant Shares shall, and hereby agrees to,
indemnify and hold harmless the Company and each of its directors, officers,
employees and agents, each other person, if any, who controls the Company and
each other seller and such seller's directors, officers, stockholders, partners,
employees, agents and affiliates from and against any and all Losses to which
they or any of them may become subject under the Securities Act, the Exchange
Act, or other federal or state statutory law or regulation, at common law or
otherwise, insofar as such losses, claims, damages, or liabilities (or actions
in respect thereof) arise out of or are based upon (i) any untrue statement or
alleged untrue statement of a material fact contained in the Registration
Statement, or any amendment thereof, or in any Preliminary Prospectus or the
Prospectus, or any amendment thereof or supplement thereto, or in a Blue Sky
Application, or (ii) the omission or the alleged omission to state in any such
Registration Statement, Preliminary Prospectus or Prospectus, amendment thereof
or supplement thereto, or Blue Sky Application a material fact required to be
stated therein or necessary to make the statements made therein not misleading,
in each case to the extent, but only to the extent, that the same was made
therein or omitted therefrom in reliance upon and in conformity with written
information furnished to the Company by or on behalf of such holder specifically
for use in the preparation thereof, and agrees to reimburse each such
indemnified party for any legal or other expenses reasonably incurred by it in
connection with investigating or defending against any such loss, claim, damage,
liability or action. The indemnify provided for in this Section 10(e)(ii) shall
remain in full force and effect regardless of any investigation made by or on
behalf of the indemnified party and shall survive any transfer of the Warrant
Shares by the indemnified party. This indemnity agreement will be in addition to
any liability that the Company may otherwise have.

      (iii) Within five (5) business days after receipt by an indemnified party
under Section 10(e)(i) or (ii) of this Warrant of notice of the commencement of
any action, such indemnified party shall, if a claim in respect thereof is to be
made against an indemnifying party under such subsection, notify the
indemnifying party in writing of the commencement thereof; the failure so to

                                      -7-
<PAGE>

notify the indemnifying party shall relieve the indemnifying party from any
liability under this Section 8 as to the particular item for which
indemnification is then being sought, unless such indemnifying party has
otherwise received actual notice of the action at least thirty (30) days before
any answer or response is required by the indemnifying party in its defense of
such action, but will not relieve it from any liability that it may have to any
indemnified party otherwise than under this Section 10. If any such action is
brought against any indemnified party and it notifies the indemnifying party of
the commencement thereof, the indemnifying party will be entitled to participate
therein and, to the extent that it may elect by written notice delivered to the
indemnified party promptly after receiving the aforesaid notice from such
indemnified party, to assume the defense thereof; provided, that if the
defendants in any such action include both the indemnified party and the
indemnifying party and either (i) the indemnifying party or parties agree, or
(ii) in the opinion of counsel for the indemnifying parties, representation of
both the indemnifying party or parties and the indemnified party or parties by
the same counsel is inappropriate under applicable standards of professional
conduct because of actual or potential conflicting interests between them, then
the indemnified party or parties shall have the right to select separate counsel
to assume such legal defense and to otherwise participate in the defense of such
action. The indemnifying party will not be liable to such indemnified party
under this Section 10 for any legal or other expenses subsequently incurred by
such indemnified party in connection with the defense thereof unless (x) the
indemnified party shall have employed counsel in connection with the assumption
of legal defenses in accordance with the proviso to the immediately preceding
sentence (it being understood, however, that the indemnifying party shall not be
liable for the expenses of more than one separate counsel in each jurisdiction
which counsel is approved by indemnified parties (whether pursuant to this
Agreement or other agreements if the claim relates to the same or similar
allegations) holding a majority of the shares as to which indemnification is
claimed), (ii) the indemnifying party shall not have employed counsel to
represent the indemnified party within a reasonable time after notice of
commencement of the action, or (iii) the indemnifying party has authorized the
employment of counsel for the indemnified party at the expense of the
indemnifying party. In no event shall an indemnifying party be liable under this
Section 10 for any settlement, effected without its written consent, which
consent shall not be unreasonably withheld, of any claim or action against an
indemnified party.

      (iv) If the indemnification provided for in this Section 10 shall for any
reason be unavailable to an indemnified party under Section 10(d)(i) and (ii) of
this Warrant in respect of any Losses, then, in lieu of the amount paid or
payable under said Section 10(e)(i) or (ii), the indemnified party and the
indemnifying party under said Section 10(e)(i) or (ii) shall contribute to the
aggregate Losses (including legal or other expenses reasonably incurred in
connection with investigating the same) (A) in such proportion as is appropriate
to reflect the relative fault of the Company and the prospective sellers of
Warrant Shares covered by the registration statement which resulted in such Loss
or action in respect thereof, with respect to the statements, omissions or
action which resulted in such Loss or action in respect thereof, as well as any
other relevant equitable considerations, or (B) if the allocation provided by
clause (A) above is not permitted by applicable law, in such proportion as shall
be appropriate to reflect the relative benefits received by the Company, on the
one hand, and such prospective sellers, on the other hand, from their sale of
Warrant Shares; provided, that, for purposes of this clause (B), the relative
benefits received by any prospective sellers shall be deemed not to exceed (and
the amount to be contributed by any prospective seller shall not exceed) the
amount received by such seller. No Person guilty of fraudulent misrepresentation
(within the meaning of Section 11(f) of the Securities Act) shall be entitled to
contribution from any Person who was not guilty of such fraudulent
misrepresentation. The obligations, if any, of the holders of Warrant Shares to
contribute as provided in this Section 10(e)(iv) are several in proportion to
the relative value of their respective Warrant Shares covered by such
registration statement and not joint. In addition, no person shall be obligated
to contribute hereunder any amounts in payment for any settlement of any action
or Losses effected without such person's consent.

                                      -8-
<PAGE>

      (f) Neither the giving of any notice by any holder nor the making of any
request for prospectuses shall impose any upon any holder making such request
any obligation to sell any Warrant Shares or exercise any Warrants.

      (g) In connection with any registration statement filed pursuant to this
Section 10, the Company shall supply prospectuses and qualify the Warrant Shares
for sale in such states, not to exceed ten, as the holders may reasonably
designates, provided, that the Company shall not be required to qualify or
register the Warrant Shares in any jurisdiction where such qualification or
registration would require the Company to submit generally to the jurisdiction
of such state.

      (h) The registration rights contained in this Section 10 shall relate to
the Warrant Shares held by the holder and any transferee unless such the holder
or such transferee may sell such Warrant Shares pursuant to Rule 144 of the
Commission under the Securities Act or any subsequent similar rule without
limitation as to the number of shares which may be sold.

      (i) The Company's agreements with respect to the Warrant Shares in this
Section 10 shall continue in effect regardless of the exercise of the Warrants.

      11. Transfer to Company with the Securities Act. Neither this Warrant or
the Warrant Shares nor any other security issued or issuable upon exercise of
this Warrant may be sold or otherwise disposed of except pursuant to an
effective registration statement under the Securities Act or an exemption from
the registration requirements of the Securities Act.

Dated as of January 25, 2006            LAWRENCE CONSULTING GROUP, INC.

                                        By:
                                           ----------------------------------
                                           Elizabeth Plaza, CEO

                                      -9-

<PAGE>

                                  PURCHASE FORM

Dated:            , 20

The undersigned hereby irrevocably exercises this Warrant to the extent of
purchasing _______ shares of Common Stock and hereby makes payment of
$____________ in payment of the Exercise Price therefor.

                     INSTRUCTIONS FOR REGISTRATION OF STOCK

Name:________________________________________________________________
                (Please typewrite or print in block letters)

Signature:___________________________________________________________

Social Security or Employer Identification No._______________________

                                 ASSIGNMENT FORM

FOR VALUE RECEIVED,__________________________________________________

hereby sells, assigns and transfer unto

Name_________________________________________________________________
               (Please typewrite or print in block letters)

Address______________________________________________________________

Social Security or Employer Identification No._______________________

The right to purchase Common Stock represented by this Warrant to the extent of
_________shares as to which such right is exercisable and does hereby
irrevocably constitute and appoint __________________ attorney to transfer the
same on the books of the Company with full power of substitution.

Dated:            , 20

Signature_________________________________________

Signature Medallion Guaranteed:

__________________________________________________

                                      -10-NOTE PURCHASE AGREEMENT

      This NOTE PURCHASE AGREEMENT (this "Agreement"), dated as of January 27,
2006, is entered into by and among Medical Media Television, Inc., a Florida
corporation (the "Company"), and CapitalSmart, LLC, a California limited
liability company (the "Purchaser"), for the issuance and sale to the Purchaser
of the Note (as defined below) of the Company, in the manner, and upon the
terms, provisions and conditions set forth in this Agreement.

      WHEREAS, the parties desire that, upon the terms and subject to the
conditions contained herein, the Company shall issue and sell to the Purchaser
and the Purchaser shall purchase the Note;

      WHEREAS, such issuance and sale will be made in reliance upon the
provisions of Section 4(2) and/or Rule 506 of Regulation D ("Regulation D") of
the United States Securities Act of 1933, as amended, and regulations
promulgated thereunder (the "Securities Act"), or upon such other exemption from
the registration requirements of the Securities Act as may be available with
respect to the purchase of the Note to be made hereunder.

      NOW, THEREFORE, in consideration of the representations, warranties and
agreements contained herein and other good and valuable consideration, the
receipt and legal adequacy of which is hereby acknowledged by the parties, the
Company and the Purchaser hereby agree as follows:

      1. Purchase and Sale of Note.

      (a) Terms of Note: Upon the following terms and subject to the conditions
contained herein, the Company shall issue and sell to the Purchaser, and the
Purchaser shall purchase from the Company, a convertible promissory note in the
aggregate principal amount of $1,000,000 (the "Purchase Price"), in
substantially the form attached hereto as Exhibit A (the "Note"), pursuant to
the following loan schedule:

                 February 15, 2006                  $250,000
                 March 31, 2006                     $750,000

      The outstanding principal amount of the Note, plus any accrued but unpaid
interest thereon, shall be due and payable in cash on the Maturity Date (as
defined in the Note); provided, however, the Purchaser shall have the sole
option to convert on the Maturity Date the outstanding principal amount of the
Note plus any accrued but unpaid interest into such number of shares of Common
Stock of the Company, par value $.0005 per share (the "Common Stock"), at a
fixed conversion price of $.40 per share. The Note shall not be convertible
until the Maturity Date and shall not be convertible such that the Investor's
overall Common Stock ownership position in the Company exceeds 4.99% (the
"Ownership Cap Restriction"); provided, however, that upon the holder of the
Note providing the Company with sixty-one (61) days notice (the "Waiver Notice")
that the holder would like to waive the Ownership Cap Restriction with regard to
any or all shares of Common Stock issuable upon exercise of the conversion
feature of the Note, this Ownership Cap Restriction will be of no force or
effect with regard to all or a portion of the Note referenced in the Waiver
Notice, and provided further that this Ownership Cap Restriction shall be of no
further force or effect during the sixty-one (61) days immediately preceding the
expiration of the term of the Note.

<PAGE>

      The Note shall bear interest at a rate of twenty percent (20%) per annum,
compounded semi-annually. Interest shall be paid at the end of each quarter in
either (i) shares of Series C Zero Coupon Preferred Stock of the Company valued
at $1.00 per share, or (ii) cash, at Investor's option, with the first interest
payment being on March 31, 2006. The Series C Zero Coupon Preferred Stock shall
be convertible into shares of the Company's Common Stock on the Maturity date at
a ten percent (10%) discount to the then-current market price based on the
average closing price for the twenty (20) days immediately preceding the
conversion. The Series C Zero Coupon Preferred Stock is subordinate to Series A
Zero Coupon Preferred Stock and Series B Zero Coupon Preferred Stock. Investor
shall make his election as to receipt of interest in cash or in Series C Zero
Coupon Preferred Stock by written notice to the Company at least five (5)
business days before the interest payment due date (the "Interest Notice Date").
If no such notice is given by Investor by such Interest Notice Date, the Company
shall pay the interest in cash.

      With the consent of both the Company and the Investor, the Note may be
extended for an additional twelve (12) months, with the terms of the interest
payments remaining the same as above.

      (b) Issuance of Warrants: The Investor will be issued 2,500,000 warrants
to purchase Common Stock of the Company (the "Warrants"). Warrants shall be
issued on a pro rata basis per the above loan schedule, as follows:

                 February 15, 2006                  625,000 warrants
                 March 31, 2006                     1,875,000 warrants

      The Warrants shall have a term of five (5) years and shall have an
exercise price equal to $0.75 per share (the "Exercise Price"). The Warrants
shall not be exercisable such that the Investor's overall Common Stock ownership
position in the Company exceeds 4.99%.

      (c) In consideration of and in express reliance upon the representations,
warranties, covenants, terms and conditions of this Agreement, the Company
agrees to issue and sell to the Purchaser and the Purchaser agrees to purchase
the Note. The closing under this Agreement (the "Closing") shall take place at
the offices of Medical Media Television, Inc., 8406 Benjamin Road, Suite C,
Tampa, Florida 33634 upon the satisfaction of each of the conditions set forth
in Sections 4 and 5 hereof (the "Closing Date").

      (d) The Company has authorized and reserved and covenants to continue to
reserve, free of preemptive rights and other similar contractual rights of
stockholders, a number of authorized but unissued shares of Common Stock to
effect the conversion of the Note. Any shares of Common Stock issuable by the
Company upon conversion of the Note are herein referred to as the "Conversion
Shares". The Note and the Conversion Shares are sometimes collectively referred
to herein as the "Securities".

                                      -2-
<PAGE>

      (e) At Company's earliest opportunity, and in any event not more than 120
days from the date hereof, all of the Conversion Shares underlying the Note and
the Warrants shall be registered pursuant to a registration statement filed with
the SEC, and such registration statement will be kept effective for a period of
3 years, subject to customary carve-outs.

      2. Representations, Warranties and Covenants of the Purchaser. The
Purchaser hereby makes the following representations and warranties to the
Company, and covenants for the benefit of the Company:

      (a) If the Purchaser is an entity, the Purchaser is a corporation, limited
liability company or partnership duly incorporated or organized, validly
existing and in good standing under the laws of the jurisdiction of its
incorporation or organization.

      (b) This Agreement has been duly authorized, validly executed and
delivered by the Purchaser and is a valid and binding agreement and obligation
of the Purchaser enforceable against the Purchaser in accordance with its terms,
subject to limitations on enforcement by general principles of equity and by
bankruptcy or other laws affecting the enforcement of creditors' rights
generally, and the Purchaser has full power and authority to execute and deliver
this Agreement and the other agreements and documents contemplated hereby and to
perform its obligations hereunder and thereunder.

      (c) The Purchaser understands that no Federal, state, local or foreign
governmental body or regulatory authority has made any finding or determination
relating to the fairness of an investment in any of the Securities and that no
Federal, state, local or foreign governmental body or regulatory authority has
recommended or endorsed, or will recommend or endorse, any investment in any of
the Securities. The Purchaser, in making the decision to purchase the
Securities, has relied upon independent investigation made by it and has not
relied on any information or representations made by third parties.

      (d) The Purchaser understands that the Securities are being offered and
sold to it in reliance on specific provisions of Federal and state securities
laws and that the Company is relying upon the truth and accuracy of the
representations, warranties, agreements, acknowledgments and understandings of
the Purchaser set forth herein for purposes of qualifying for exemptions from
registration under the Securities Act, and applicable state securities laws.

      (e) The Purchaser is an "accredited investor" as defined under Rule 501 of
Regulation D promulgated under the Securities Act.

      (f) The Purchaser is and will be acquiring the Securities for its own
account, and not with a view to any resale or distribution of the Note in whole
or in part, in violation of the Securities Act or any applicable securities
laws.

      (g) The offer and sale of the Securities is intended to be exempt from
registration under the Securities Act, by virtue of Section 4(2) and/or Rule 506
of Regulation D promulgated under the Securities Act. The Purchaser understands
that the Securities purchased hereunder have not been, and may never be,
registered under the Securities Act and that none of the Securities can be sold
or transferred unless they are first registered under the Securities Act and
such state and other securities laws as may be applicable or in the opinion of
counsel for the Company an exemption from registration under the Securities Act
is available (and then the Securities may be sold or transferred only in
compliance with such exemption and all applicable state and other securities
laws).

                                      -3-
<PAGE>

      3. Representations, Warranties and Covenants of the Company. The Company
represents and warrants to the Purchaser, and covenants for the benefit of the
Purchaser, as follows:

      (a) The Company has been duly incorporated and is validly existing and in
good standing under the laws of the State of Florida, with full corporate power
and authority to own, lease and operate its properties and to conduct its
business as currently conducted, and is duly registered and qualified to conduct
its business and is in good standing in each jurisdiction or place where the
nature of its properties or the conduct of its business requires such
registration or qualification, except where the failure to register or qualify
would not have a Material Adverse Effect. For purposes of this Agreement,
"Material Adverse Effect" shall mean any effect on the business, results of
operations, prospects, assets or financial condition of the Company that is
material and adverse to the Company and its subsidiaries and affiliates and/or
any condition, circumstance, or situation that would prohibit or otherwise
materially interfere with the ability of the Company from entering into and
performing any of its obligations under this Agreement or the Note in any
material respect.

      (b) The Note has been duly authorized by all necessary corporate action
and, when paid for or issued in accordance with the terms hereof, the Note shall
be validly issued and outstanding, free and clear of all liens, encumbrances and
rights of refusal of any kind. When the Conversion Shares are issued and paid
for in accordance with the terms of this Agreement and as set forth in the Note,
such shares will be duly authorized by all necessary corporate action and
validly issued and outstanding, fully paid and nonassessable, free and clear of
all liens, encumbrances and rights of refusal of any kind and the holders shall
be entitled to all rights accorded to a holder of Common Stock.

      (c) The Note and this Agreement (the "Transaction Documents") have been
duly authorized, validly executed and delivered on behalf of the Company and is
a valid and binding agreement and obligation of the Company enforceable against
the Company in accordance with its terms, subject to limitations on enforcement
by general principles of equity and by bankruptcy or other laws affecting the
enforcement of creditors' rights generally, and the Company has full power and
authority to execute and deliver the Transaction Documents and the other
agreements and documents contemplated hereby and to perform its obligations
hereunder and thereunder.

      (d) The execution and delivery of the Transaction Documents and the
consummation of the transactions contemplated by this Agreement by the Company,
will not (i) conflict with or result in a breach of or a default under any of
the terms or provisions of, (A) the Company's certificate of incorporation or
by-laws, or (B) of any material provision of any indenture, mortgage, deed of
trust or other material agreement or instrument to which the Company is a party
or by which it or any of its material properties or assets is bound, (ii) result
in a violation of any material provision of any law, statute, rule, regulation,
or any existing

                                      -4-
<PAGE>

applicable decree, judgment or order by any court, Federal or state regulatory
body, administrative agency, or other governmental body having jurisdiction over
the Company, or any of its material properties or assets or (iii) result in the
creation or imposition of any material lien, charge or encumbrance upon any
material property or assets of the Company or any of its subsidiaries pursuant
to the terms of any agreement or instrument to which any of them is a party or
by which any of them may be bound or to which any of their property or any of
them is subject except in the case of clauses (i)(B) or (iii) for any such
conflicts, breaches, or defaults or any liens, charges, or encumbrances which
would not have a Material Adverse Effect.

      (e) The sale and issuance of the Securities in accordance with the terms
of and in reliance on the accuracy of the Purchaser's representations and
warranties set forth in this Agreement will be exempt from the registration
requirements of the Securities Act.

      (f) No consent, approval or authorization of or designation, declaration
or filing with any governmental authority on the part of the Company is required
in connection with the valid execution and delivery of this Agreement or the
offer, sale or issuance of the Securities or the consummation of any other
transaction contemplated by this Agreement.

      (g) There is no action, suit, claim, investigation or proceeding pending
or, to the knowledge of the Company, threatened against the Company which
questions the validity of the Transaction Documents or the transactions
contemplated thereby or any action taken or to be taken pursuant thereto. There
is no action, suit, claim, investigation or proceeding pending or, to the
knowledge of the Company, threatened, against or involving the Company or any
subsidiary, or any of their respective properties or assets which, if adversely
determined, is reasonably likely to result in a Material Adverse Effect.

      (h) The Company has complied and will comply with all applicable federal
and state securities laws in connection with the offer, issuance and sale of the
Note hereunder. Neither the Company nor anyone acting on its behalf, directly or
indirectly, has or will sell, offer to sell or solicit offers to buy the Note,
or similar securities to, or solicit offers with respect thereto from, or enter
into any preliminary conversations or negotiations relating thereto with, any
person, or has taken or will take any action so as to bring the issuance and
sale of the Note under the registration provisions of the Securities Act and any
other applicable federal and state securities laws. Neither the Company nor any
of its affiliates, nor any person acting on its or their behalf, has engaged in
any form of general solicitation or general advertising (within the meaning of
Regulation D under the Securities Act) in connection with the Note.

      (i) To the Company's knowledge, neither this Agreement, nor the Schedules
hereto contain any untrue statement of a material fact or omit to state a
material fact necessary in order to make the statements made herein or therein,
in the light of the circumstances under which they were made herein or therein,
not misleading.

      (j) The authorized capital stock of the Company and the shares thereof
issued and outstanding as of January 20, 2006 are set forth on Schedule 3(j)
attached hereto. All of the outstanding shares of the Common Stock have been
duly and validly authorized, and are fully paid and non-assessable. Except as
set forth in this Agreement or on Schedule 3(j) attached hereto, as of the date
hereof, no shares of the Common Stock are entitled to preemptive rights

                                      -5-
<PAGE>

and there are no registration rights or outstanding options, warrants, scrip,
rights to subscribe to, call or commitments of any character whatsoever relating
to, or securities or rights convertible into, any shares of capital stock of the
Company. As of the date hereof, except for as set forth on Schedule 3(j), the
Company is not a party to any agreement granting registration rights to any
person with respect to any of its equity or debt securities. The Company is not
a party to, and its executive officers have no knowledge of, any agreement
restricting the voting or transfer of any shares of the capital stock of the
Company. The offer and sale of all capital stock, convertible securities,
rights, warrants, or options of the Company issued prior to the Closing complied
with all applicable federal and state securities laws, or no stockholder has a
right of rescission or damages with respect thereto which is reasonably likely
to have a Material Adverse Effect. The Company has furnished or made available
to the Purchaser true and correct copies of the Company's Certificate of
Incorporation as in effect on the date hereof (the "Certificate"), and the
Company's Bylaws as in effect on the date hereof (the "Bylaws").

      (k) So long as the Note remains outstanding, the Company shall take all
action necessary to at all times have authorized, and reserved for the purpose
of issuance, a sufficient number of shares of Common Stock to effect the
conversion of the Note.

      (l) The Company has complied and will comply with all applicable federal
and state securities laws in connection with the offer, issuance and sale of the
Note and the Conversion Shares hereunder. Neither the Company nor anyone acting
on its behalf, directly or indirectly, has or will sell, offer to sell or
solicit offers to buy any of the Securities, or similar securities to, or
solicit offers with respect thereto from, or enter into any preliminary
conversations or negotiations relating thereto with, any person, or has taken or
will take any action so as to bring the issuance and sale of any of the
Securities under the registration provisions of the Securities Act and
applicable state securities laws. Neither the Company nor any of its affiliates,
nor any person acting on its or their behalf, has engaged in any form of general
solicitation or general advertising (within the meaning of Regulation D under
the Securities Act) in connection with the offer or sale of any of the
Securities.

      (m) The Company agrees that so long as the Note is outstanding or the
Purchaser owns at least 2,000,000 shares of Common Stock on a fully diluted
basis, the Purchaser shall have the right to nominate or appoint an individual
to serve as an observer of the Company's board of directors.

      4. Conditions Precedent to the Obligation of the Company to Sell the Note.
The obligation hereunder of the Company to issue and sell the Note to the
Purchaser is subject to the satisfaction or waiver, at or before the Closing
Date, of each of the conditions set forth below. These conditions are for the
Company's sole benefit and may be waived by the Company at any time in its sole
discretion.

      (a) The Purchaser shall have executed and delivered this Agreement.

      (b) The Purchaser shall have performed, satisfied and complied in all
material respects with all covenants, agreements and conditions required to be
performed, satisfied or complied with by the Purchaser at or prior to the
Closing Date.

                                      -6-
<PAGE>

      (c) The representations and warranties of the Purchaser shall be true and
correct in all material respects as of the date when made and as of the Closing
Date as though made at that time, except for representations and warranties that
are expressly made as of a particular date, which shall be true and correct in
all material respects as of such date.

      (d) At the Closing Date, the Purchaser shall have delivered to the Company
immediately available funds as payment in full of the Purchase Price for the
Note.

      5. Conditions Precedent to the Obligation of the Purchaser to Purchase the
Note. The obligation hereunder of the Purchaser to acquire and pay for the Note
is subject to the satisfaction or waiver, at or before the Closing Date, of each
of the conditions set forth below. These conditions are for the Purchaser's sole
benefit and may be waived by the Purchaser at any time in its sole discretion.

      (a) The Company shall have executed and delivered the Note, this Agreement
and any other Transaction Document.

      (b) The Company shall have performed, satisfied and complied in all
material respects with all covenants, agreements and conditions required by the
Transaction Documents to be performed, satisfied or complied with by the Company
at or prior to the Closing Date.

      (c) Each of the representations and warranties of the Company shall be
true and correct in all material respects as of the date when made and as of the
Closing Date as though made at that time (except for representations and
warranties that speak as of a particular date), which shall be true and correct
in all material respects as of such date.

      (d) No statute, regulation, executive order, decree, ruling or injunction
shall have been enacted, entered, promulgated or endorsed by any court or
governmental authority of competent jurisdiction which prohibits the
consummation of any of the transactions contemplated by this Agreement at or
prior to the Closing Date.

      (e) As of the Closing Date, no action, suit or proceeding before or by any
court or governmental agency or body, domestic or foreign, shall be pending
against or affecting the Company, or any of its properties, which questions the
validity of the Agreement, the Note, or the transactions contemplated thereby or
any action taken or to be take pursuant thereto. As of the Closing Date, no
action, suit, claim or proceeding before or by any court or governmental agency
or body, domestic or foreign, shall be pending against or affecting the Company,
or any of its properties, which, if adversely determined, is reasonably likely
to result in a Material Adverse Effect.

      (f) No Material Adverse Effect shall have occurred at or before the
Closing Date.

      (g) The Company shall have delivered on the Closing Date to the Purchaser
a secretary's certificate, dated as of the Closing Date, as to (i) the
resolutions of the board of directors of the Company authorizing the
transactions contemplated by this Agreement, (ii) the Certificate, (iii) the
Bylaws, each as in effect at the Closing, and (iv) the authority and incumbency
of the officers of the Company executing this Agreement and the Note.

                                      -7-
<PAGE>

      (h) The Purchaser shall have received a legal opinion in substantially the
form annexed hereto as Exhibit B as of the Closing Date.

      6. Legend. Each Note and certificate representing the Conversion Shares
shall be stamped or otherwise imprinted with a legend substantially in the
following form (in addition to any legend required by applicable state
securities or "blue sky" laws):

         "THE  SECURITIES  REPRESENTED BY THIS  CERTIFICATE  (THE
         "SECURITIES")   HAVE  NOT  BEEN  REGISTERED   UNDER  THE
         SECURITIES  ACT OF 1933,  AS  AMENDED  (THE  "SECURITIES
         ACT") OR ANY STATE  SECURITIES LAWS AND MAY NOT BE SOLD,
         TRANSFERRED OR OTHERWISE  DISPOSED OF UNLESS  REGISTERED
         UNDER  THE  SECURITIES  ACT AND UNDER  APPLICABLE  STATE
         SECURITIES LAWS OR MEDICAL MEDIA TELEVISION,  INC. SHALL
         HAVE RECEIVED AN OPINION OF COUNSEL THAT REGISTRATION OF
         SUCH  SECURITIES  UNDER THE SECURITIES ACT AND UNDER THE
         PROVISIONS OF APPLICABLE  STATE  SECURITIES  LAWS IS NOT
         REQUIRED."

The Company agrees to reissue the Note and certificates representing the
Conversion Shares, without the legend set forth above if at such time, prior to
making any transfer of any such Securities, such holder thereof shall give
written notice to the Company describing the manner and terms of such transfer
and removal as the Company may reasonably request. Such proposed transfer will
not be effected until: (a) the Company has notified such holder that either (i)
in the opinion of its counsel, the registration of the Note or Conversion Shares
under the Securities Act is not required in connection with such proposed
transfer; or (ii) a registration statement under the Securities Act covering
such proposed disposition has been filed by the Company with the Securities and
Exchange Commission and has become effective under the Securities Act; and (b)
the Company has notified such holder that either: (i) in the opinion of its
counsel, the registration or qualification under the securities or "blue sky"
laws of any state is not required in connection with such proposed disposition,
or (ii) compliance with applicable state securities or "blue sky" laws has been
effected. The Company will use its best efforts to respond to any such notice
from a holder within five (5) days. In the case of any proposed transfer under
this Section 6, the Company will use reasonable efforts to comply with any such
applicable state securities or "blue sky" laws, but shall in no event be
required, in connection therewith, to qualify to do business in any state where
it is not then qualified or to take any action that would subject it to tax or
to the general service of process in any state where it is not then subject. The
restrictions on transfer contained in this Section 6 shall be in addition to,
and not by way of limitation of, any other restrictions on transfer contained in
any other section of this Agreement.

                                      -8-
<PAGE>

      7. Fees and Expenses. Each party shall pay the fees and expenses of its
advisors, counsel, accountants and other experts, if any, and all other
expenses, incurred by such party incident to the negotiation, preparation,
execution, delivery and performance of this Agreement, provided, however, that
the Company shall pay (i) $10,000 of non-accountable fees and expenses in
connection with the due diligence, preparation, negotiation, execution and
delivery of this Agreement, the Note and the transactions contemplated
thereunder and (ii) the costs of any amendments, modifications or waivers of
this Agreement, the Note or any other Transaction Document.

      8. Indemnification.

      (a) The Company hereby agrees to indemnify and hold harmless the Purchaser
and its officers, directors, shareholders, employees, agents and attorneys
against any and all losses, claims, damages, liabilities and reasonable expenses
(collectively "Claims") incurred by each such person in connection with
defending or investigating any such Claims, whether or not resulting in any
liability to such person, to which any such indemnified party may become
subject, insofar as such Claims arise out of or are based upon any breach of any
representation or warranty or agreement made by the Company in this Agreement.

      (b) The Purchaser hereby agrees to indemnify and hold harmless the Company
and its officers, directors, shareholders, employees, agents and attorneys
against any and all losses, claims, damages, liabilities and expenses incurred
by each such person in connection with defending or investigating any such
claims or liabilities, whether or not resulting in any liability to such person,
to which any such indemnified party may become subject under the Securities Act,
or under any other statute, at common law or otherwise, insofar as such Claims
arise out of or are based upon (i) any untrue statement or alleged untrue
statement of a material fact made by the Purchaser, (ii) any omission or alleged
omission of a material fact with respect to the Purchaser or (iii) any breach of
any representation, warranty or agreement made by the Purchaser in this
Agreement.

      9. Governing Law; Consent to Jurisdiction. This Agreement shall be
governed by and interpreted in accordance with the laws of the State of Florida
without giving effect to the rules governing the conflicts of laws. Each of the
parties consents to the exclusive jurisdiction of the Federal courts whose
districts encompass any part of the County of Hillsborough located in the City
of Tampa in connection with any dispute arising under this Agreement and hereby
waives, to the maximum extent permitted by law, any objection, including any
objection based on forum non conveniens, to the bringing of any such proceeding
in such jurisdictions. Each party waives its right to a trial by jury. Each
party to this Agreement irrevocably consents to the service of process in any
such proceeding by the mailing of copies thereof by registered or certified
mail, postage prepaid, to such party at its address set forth herein. Nothing
herein shall affect the right of any party to serve process in any other manner
permitted by law.

      10. Notices. All notices and other communications provided for or
permitted hereunder shall be made in writing by hand delivery, express overnight
courier, registered first class mail, or telecopier (provided that any notice
sent by telecopier shall be confirmed by other means pursuant to this Section
10), initially to the address set forth below, and thereafter at such other
address, notice of which is given in accordance with the provisions of this
Section.

                                      -9-
<PAGE>

      (a)      if to the Company:

               Medical Media Television, Inc.
               8406 Benjamin Road, Suite C
               Tampa, Florida 33634
               Attention: Philip M. Cohen, President/Chief Executive Officer
               Tel. No.: (813) 888-7330
               Fax No.:  (813) 888-7375

               with a copy to:

               Bush Ross Gardner Warren & Rudy, P.A.
               220 S. Franklin St.
               Tampa, FL  33601
               Attn:  John N. Giordano
               Tel. No.:  (813) 224-9255
               Fax No.:  (813) 223-9620

      (b)      if to the Purchaser:

               CapitalSmart, LLC
               1112 League Line Rd
               Conroe, TX 77303
               Attn: William Quiros
               Tel. No.:  (818) 284-0496
               Fax No.:  (708) 575-7985

All such notices and communications shall be deemed to have been duly given:
when delivered by hand, if personally delivered; when receipt is acknowledged,
if telecopied; or when actually received or refused if sent by other means.

      11. Assignment. Neither party may assign, sell, or transfer to any third
person the rights of such party hereunder; provided, however, that Purchaser may
assign his rights hereunder to an entity wholly owned and controlled by
Purchaser.

      12. Entire Agreement. This Agreement, the Note and any other Transaction
Document constitute the entire understanding and agreement of the parties with
respect to the subject matter hereof and supersedes all prior and/or
contemporaneous oral or written proposals or agreements relating thereto all of
which are merged herein. This Agreement may not be amended or any provision
hereof waived in whole or in part, except by a written amendment signed by both
of the parties.

      13. Counterparts. This Agreement may be executed by facsimile signature
and in counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.

                                  [end of page]

                                      -10-
<PAGE>

      IN WITNESS WHEREOF, this Agreement was duly executed on the date first
written above.

                           MEDICAL MEDIA TELEVISION, INC.

                           By: /s/  Philip M. Cohen
                               -------------------------------------------------
                                Name:  Philip M. Cohen
                                Title: President and Chief Executive Officer

                           PURCHASER:

                           CapitalSmart, LLC

                           By: /s/ William Quiros
                               -------------------------------------------------
                                Name:  William Quiros
                                Title: Managing Member

                                      -11-

<PAGE>

                                    EXHIBIT A
                                  FORM OF NOTE

                                      -12-

<PAGE>

                                    EXHIBIT B
                                 FORM OF OPINION

      1. The Company is a corporation duly incorporated, validly existing and in
good standing under the laws of the State of Florida and has the requisite
corporate power to own, lease and operate its properties and assets, and to
carry on its business as presently conducted. The Company is duly qualified as a
foreign corporation to do business and is in good standing in every jurisdiction
in which the failure to so qualify would have a Material Adverse Effect.

      2. The Company has the requisite corporate power and authority to enter
into and perform its obligations under the Transaction Documents and to issue
the Securities. The execution, delivery and performance of the Transaction
Documents by the Company and the consummation by it of the transactions
contemplated thereby have been duly and validly authorized by all necessary
corporate action and no further consent or authorization of the Company or its
Board of Directors is required. The Transaction Documents have been duly
executed and delivered, and the Note has been duly executed, issued and
delivered by the Company and each Transaction Document constitutes a legal,
valid and binding obligation of the Company enforceable against the Company in
accordance with its respective terms. The Conversion Shares are not subject to
any preemptive rights under the Certificate of Incorporation or the Bylaws.

      3. The Note has been duly authorized and, when delivered against payment
in full as provided in the Purchase Agreement, will be validly issued. The
Conversion Shares have been duly authorized for issuance, and when delivered
upon conversion or against payment in full as provided in the Note, will be
validly issued, fully paid and nonassessable.

      4. The execution, delivery and performance of and compliance with the
terms of the Transaction Documents and the issuance of the Securities do not (a)
violate any provision of the Certificate of Incorporation or Bylaws, (b) to our
knowledge, after due inquiry, conflict with, or constitute a default (or an
event which with notice or lapse of time or both would become a default) under,
or give to others any rights of termination, amendment, acceleration or
cancellation of, any material agreement, mortgage, deed of trust, indenture,
note, bond, license, lease agreement, instrument or obligation to which the
Company is a party and which is known to us, (c) to our knowledge, after due
inquiry, create or impose a lien, charge or encumbrance on any property of the
Company under any agreement or any commitment known to us to which the Company
is a party or by which the Company is bound or by which any of its respective
properties or assets are bound, or (d) result in a violation of any Federal,
state, local or foreign statute, rule, regulation, order, judgment, injunction
or decree (including Federal and state securities laws and regulations)
applicable to the Company or by which any property or asset of the Company is
bound or affected, except, in all cases other than violations pursuant to
clauses (a) and (d) above, for such conflicts, default, terminations,
amendments, acceleration, cancellations and violations as would not,
individually or in the aggregate, have a Material Adverse Effect.

      5. No consent, approval or authorization of or designation, declaration or
filing with any governmental authority on the part of the Company is required
under Federal, state or local law, rule or regulation in connection with the
valid execution, delivery and performance of the Transaction Documents, or the
offer, sale or issuance of the Note or the Conversion Shares.

                                      -13-
<PAGE>

      6. To our knowledge, there is no action, suit, claim, investigation or
proceeding pending or threatened against the Company which questions the
validity of the Purchase Agreement or the transactions contemplated thereby or
any action taken or to be taken pursuant thereto. There is no action, suit,
claim, investigation or proceeding pending, or to our knowledge, threatened,
against or involving the Company or any of its properties or assets and which,
if adversely determined, is reasonably likely to result in a Material Adverse
Effect. There are no outstanding orders, judgments, injunctions, awards or
decrees of any court, arbitrator or governmental or regulatory body against the
Company or any officers or directors of the Company in their capacities as such.

         7. Conditioned on the accuracy of the Purchaser's representations and
warranties contained in the Purchase Agreement, the offer, issuance and sale of
the Note and the offer, issuance and sale of the Conversion Shares pursuant to
the Purchase Agreement and the Note, as applicable, are exempt from the
registration requirements of the Securities Act of 1933, as amended.

                                      -14-

<PAGE>

                                   SCHEDULE 3j

Medical Media Television, Inc. Capital Stock:
---------------------------------------------

Common Stock:     Authorized Shares:               100,000,000 shares
------------
                  Outstanding Shares:               20,971,299 shares
                  Par Value:                        $.0005

Preferred Stock:  Total Authorized Shares:          25,000,000 shares
---------------
                  Total Outstanding Shares:          4,303,959 shares
                  Par Value:                         Zero

Series A Zero Coupon Preferred Stock:  Authorized Shares:      1,682,044 shares
------------------------------------
                                       Outstanding Shares:     1,682,044 shares

Series B Zero Coupon Preferred Stock:  Authorized Shares:      2,612,329 shares
------------------------------------
                                       Outstanding Shares:     2,612,329 shares

Series C Zero Coupon Preferred Stock:  Authorized Shares:        400,000 shares
-------------------------------------
                                       Outstanding Shares:         9,586 shares

           OUTSTANDING OPTIONS, WARRANTS, AND OTHER RIGHTS TO ACQUIRE
                    SHARES OF MEDICAL MEDIA TELEVISION, INC.

Outstanding stock options to purchase 5,303 shares of common stock of MMTV.

Outstanding warrants to purchase 10,879,235 shares of common stock of MMTV.

Outstanding Series A and Series B preferred shares which will convert into
16,093,989 shares of common stock of MMTV.

Outstanding Series C preferred shares (8,627) which will convert into common
shares at a discount to market at time of conversion.

Outstanding convertible debentures which will convert into 6,987,952 shares of
common stock of MMTV. These convertible debentures may be repaid in cash at the
option of the Company.

The above calculations do not include any shares of Series C preferred stock
that may be issued for interest payments on existing convertible debt
instruments that will be converted into common shares at a discount to market at
time of conversion. It also does not include any common shares that may be
issued for interest payments on existing convertible debt instruments.

                                      -15-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00096-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00096-of-00352.parquet"}]]